Genomic alterations were reviewed by the Institute's molecular tumor board and recommendations for patient treatment options were made regarding
genomically targeted therapies either already approved or used investigationally — including clinical trials.
Sharma and Allison close by noting that federal funding for cancer research has been «overwhelmingly directed toward
genomically targeted therapies.»
The prospect of combining
genomically targeted therapies with drugs that free the immune system to attack cancer suggests «we are finally poised to deliver curative therapies to cancer patients,» researchers at The University of Texas MD Anderson Cancer Center note in a review in the April 9 edition of Cell.
There's a school of thought, Sharma notes, that combining multiple
genomically targeted therapies might prove effective.